Consider writing about:
Glenmark Pharmaceuticals’ agreement to pay $29.6 million to resolve allegations that the company harmed consumers by manipulating the prices of generic medicines and reducing competition; what to know about states’ scrutiny of suspected price-fixing in the pharmaceutical sector; what enforcement trends regarding generic drug pricing illustrate regarding state AGs’ powers and priorities; and perhaps a broader look at trends this year involving price-fixing allegations against drug manufacturers.